National Institutes of Health (NIH): Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)

This opportunity uses the R21/R23 Phased Innovation Award funding mechanism.

Applications are invited to support early stage translational research focused on the discovery and development of novel therapeutics against select eukaryotic pathogens.

Funding & Duration

Application budgets are limited to US $275,000 (approx. AUD $380,000) in direct costs over the two-year project period, with a maximum of $200,000 (approx. AUD $276,000) in direct costs allowed in any single year.

The R33 award phase is limited to $300,000 (approx. AUD $414,000) in direct costs per year.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Dates

  • 10 January 2016 – Letter of Intent (LOI) via Grants.Gov submission portal.
  • Copy of LOI forwarded to the Research Branch ASAP.
  • 27 January 2016 – full applications (by invitation only) submitted to the Research Branch for internal review.

Grants Officer: Dr Don McMaster


Further Information

This entry was posted in Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding and tagged . Bookmark the permalink.

Comments are closed.